Efficacy of low‐dose topotecan in second‐line treatment for patients with epithelial ovarian carcinoma

The high incidence of dose‐limiting myelosuppresion using the U.S. Food and Drug Administration‐approved topotecan dose of 1.5 mg/m2 for 5 days every 3 weeks may have limited its utility in the treatment of patients with epithelial ovarian carcinoma. The objective of the study was to evaluate the treatment results and toxicity of a low‐dose topotecan regimen as second‐line treatment for patients with epithelial ovarian carcinoma.

[1]  H. Hansen,et al.  Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. , 2001, Gynecologic oncology.

[2]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Markman,et al.  Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. , 2000, Gynecologic oncology.

[4]  H. V. van Houwelingen,et al.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Deppe,et al.  Advances in ovarian cancer chemotherapy. , 2000, Current opinion in oncology.

[6]  C. Hoppel,et al.  A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. , 2000, Gynecologic oncology.

[7]  C. Dunton,et al.  Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Morgan,et al.  Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial. , 1999, Gynecologic oncology.

[9]  C. Runowicz,et al.  Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Lissoni,et al.  Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Mcguire Wp,et al.  Chemotherapy of advanced ovarian cancer. , 1998 .

[12]  E. Eisenhauer,et al.  Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Markman.  "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer? , 1998, Gynecologic oncology.

[14]  R. Ozols.  Treatment of recurrent ovarian cancer: increasing options--"recurrent" results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A Gordon,et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Gore,et al.  Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Edmund E. Kim,et al.  Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H E Lambert,et al.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Rustin,et al.  Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  L. Saltz,et al.  Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. , 1993, Journal of the National Cancer Institute.

[21]  H. Hansen,et al.  Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  L. Grochow,et al.  Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Houghton,et al.  Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors , 2004, Cancer Chemotherapy and Pharmacology.

[24]  C. Rodenburg,et al.  Chemotherapy in advanced ovarian cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[25]  F. Parazzini,et al.  Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel. , 2001, Gynecologic oncology.

[26]  F. Parazzini,et al.  Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. , 1999, Gynecologic oncology.

[27]  M. Gore,et al.  Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.